Pertuzumab

Pertuzumab (brand name: Perjeta) is a monoclonal antibody medication used to treat certain types of breast cancer. It is given in combination with other medications, such as trastuzumab, to reduce the risk of cancer spread or recurrence. Pertuzumab binds to a protein on the surface of some cancer cells, preventing them from growing and dividing.

Pertuzumab, also known by the brand name Perjeta, is a medication used to treat a specific type of breast cancer. Here's a breakdown of its key features:

Function:

• Pertuzumab is a monoclonal antibody, a type of engineered protein designed to target specific cells.
• In breast cancer treatment, it targets a protein called HER2 (human epidermal growth factor receptor 2) found on the surface of some cancer cells. By attaching to HER2, pertuzumab blocks it from sending signals that tell the cancer cells to grow and divide.

Applications:

• Pertuzumab is primarily used for HER2-positive breast cancer, an aggressive form of breast cancer where the cancer cells have an overabundance of the HER2 protein.
• It's typically used in combination with other medications, such as trastuzumab (Herceptin) and docetaxel (Taxotere), to treat:
  • Metastatic breast cancer: Cancer that has spread to other parts of the body from the breast.
  • Early-stage breast cancer: Pertuzumab may be used before surgery (neoadjuvant therapy) or after surgery (adjuvant therapy) to help prevent recurrence.

Benefits:

• Pertuzumab, along with other medications, can improve treatment outcomes for HER2-positive breast cancer, including increased progression-free survival (time without the cancer worsening) and overall survival rates.

Important Considerations:

• Side effects: Pertuzumab can cause side effects like diarrhea, rash, nausea, fatigue, and low blood levels of certain minerals. Serious side effects, though uncommon, can include heart problems and infusion reactions.
• Not for everyone: Pertuzumab is only for HER2-positive breast cancer and is not effective for other types of cancer.
• Administered by injection: Pertuzumab is given intravenously (into a vein) by a healthcare professional.